Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedinexSGX:OTX 58 EBITDA Margin % is 7.23% as of Mar. 2026, which is 76% below its 10-year median of 30.67. GuruFocus rates SGX:OTX with a GF Score™ of 58/100 and a GF Value™ of S$0.20 (Fairly Valued). The stock has 7 warning signs investors should review. Among 662 Healthcare Providers & Services companies, Medinex ranks better than 83.23% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medinex's EBITDA for the
six
months ended in Mar. 2026 was S$0.46 Mil. Medinex's Revenue for the
six
months ended in Mar. 2026 was S$6.37 Mil. Therefore, Medinex's EBITDA margin for the quarter that ended in Mar. 2026 was 7.23%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medinex EBITDA Margin % Related Terms
Medinex EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medinex's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:OTX vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Medinex's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinex EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medinex's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medinex's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medinex (SGX:OTX) has a EBITDA Margin % of 7.23% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medinex and its competitors. This is 76% below median its historical median of 30.67. Over the past decade, Medinex's EBITDA Margin % has ranged from 13.83 to 46.20. According to the industry distribution chart, Medinex ranks #111 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 16.8%.
Is Medinex's EBITDA Margin % too high?
Medinex's current EBITDA Margin % of 7.23% is 76% below median its 10-year median of 30.67. Over the past 10 years, this metric has ranged from a low of 13.83 to a high of 46.20. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Medinex's value of 7.23% is 29.4% below this industry median. Based on the distribution chart, Medinex ranks #111 out of 662 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Medinex has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medinex's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Medinex ranks #111 out of 662 companies for EBITDA Margin %. This places Medinex in the top 17% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.24. Medinex's value of 7.23% is 29.4% below this benchmark. Historically, Medinex's own EBITDA Margin % has ranged from 13.83 to 46.20 over the past decade. While the company's 10-year median is 30.67 vs. the industry median of 10.24, Medinex has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medinex's current EBITDA Margin % of 7.23% is 29.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medinex and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinex's current EBITDA Margin % is 7.23%, which is 76% below median its own 10-year median of 30.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinex stock overvalued right now?
Based on GuruFocus' analysis, Medinex (SGX:OTX) is currently considered Fairly Valued. The stock's GF Value™ is S$0.20, compared to a current price of S$0.22 — trading 10% above its estimated fair value. The current EBITDA Margin % is 7.23%, which is 76% below median its 10-year median of 30.67 and 29.4% below the Healthcare Providers & Services industry median of 10.24. Medinex's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medinex (SGX:OTX), the current EBITDA Margin % is 7.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinex (SGX:OTX) Overvalued in 2026?
Based on GuruFocus' analysis, Medinex stock appears to be overvalued.
The current stock price of S$0.22 is trading 10% above its estimated GF Value™ of S$0.20.
GuruFocus considers Medinex to be Fairly Valued.
Key valuation signals for SGX:OTX:
EBITDA Margin %: 7.23% (76% below median its 10-year median of 30.67)
GF Value™: S$0.20 vs. price of S$0.22 (10% above fair value)
Industry Position: 29.4% below the Healthcare Providers & Services median (#111 of 662)
No single metric tells the full story. See the SGX:OTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinex Ltd is an investment holding company. The company has four business segments: Medical Support Services, Business Support Services, Pharmaceutical Services, and Medical Services. The company generates maximum revenue from the Business Support Services segment. The Business support services business segment provides professional services to customer base who are outside from healthcare industry.
58GF Score
Get the complete analysis for SGX:OTX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:OTX has been successfully added to your 
